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Objective. Platelet-derived growth factor (PDGF)
and its receptor, PDGFR, promote fibrosis in systemic
sclerosis (SSc; scleroderma) dermal fibroblasts, and
such cells in scleroderma skin lesions produce excessive
reactive oxygen species (ROS). PDGFR is phosphory-
lated upon PDGF stimulation, and is dephosphorylated
by protein tyrosine phosphatases (PTPs), including
PTP1B. This study was undertaken to determine
whether the thiol-sensitive PTP1B is affected by ROS in
SSc dermal fibroblasts, thereby enhancing the phos-
phorylation of PDGFR and synthesis of type I collagen.
This study also sought to investigate the effect of a thiol
antioxidant, N-acetylcysteine (NAC), in SSc.
Methods. Fibroblasts were isolated from the skin
of patients with diffuse SSc and normal healthy donors
for cell culture experiments and immunofluorescence
analyses. A phosphate release assay was used to deter-
mine the activity of PTP1B.
Results. Levels of ROS and type I collagen were
significantly higher and amounts of free thiol were
significantly lower in SSc fibroblasts compared to nor-
mal fibroblasts. After stimulation with PDGF, not only
were PDGFR and ERK-1/2 phosphorylated to a greater
extent, but also the ability to produce PTP1B was
hampered in SSc fibroblasts. The activity of PTP1B was
significantly inactivated in SSc fibroblasts as a result of
cysteine oxidation by the raised levels of ROS, which
was confirmed by the oxidation of multiple PTPs, in-
cluding PTP1B, in SSc fibroblasts. Decreased expres-
sion of PTP1B in normal fibroblasts led to increased
expression of type I collagen. Treatment of the cells with
NAC restored the activity of PTP1B, improved the
profile of PDGFR phosphorylation, decreased the num-
bers of tyrosine-phosphorylated proteins and levels of
type I collagen, and scavenged ROS in SSc fibroblasts.
Conclusion. This study describes a new mecha-
nism by which ROS may promote a profibrotic pheno-
type in SSc fibroblasts through the oxidative inactiva-
tion of PTP1B, leading to pronounced activation of
PDGFR. The study also presents a novel molecular
mechanism by which NAC may act on ROS and PTP1B
to provide therapeutic benefit in SSc.
Systemic sclerosis (SSc; scleroderma) is charac-
terized by Raynaud’s phenomenon, proliferative vascu-
lar lesions, and fibrosis of the skin and internal organs.
The exact mechanism of tissue scarring is still unknown.
However, the abnormal phenotype has been suggested
to be due to excessive production of extracellular matrix
components, such as type I collagen, by fibroblasts (1).
These cells proliferate rapidly and stain positive for
-smooth muscle actin, and therefore possess a myofi-
broblast phenotype (2).
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Previous results have suggested that platelet-
derived growth factor (PDGF) and its receptor, PDGFR,
are key elements in fibrosis. Increased PDGF activity
has been observed in plasma-derived serum from pa-
tients with SSc (3). Immunohistologic studies of skin
biopsy samples have revealed that the expression of
PDGF and PDGFR is increased in the skin of patients
with SSc (4,5). Cytokines, such as transforming growth
factor  (TGF) and interleukin-1, stimulate the ex-
pression of PDGFR and the production of PDGF in
SSc fibroblasts, and appear to be critical for promoting
fibrosis in SSc fibroblasts (6,7). PDGF stimulates the
Ras–ERK-1/2–reactive oxygen species (ROS) signaling
pathway, which results in stimulation of genes encoding
human collagen (COL) (8). All of these studies provide
evidence of the importance of PDGFR signaling in the
development of skin lesions in SSc.
ROS, such as superoxide (O2
 ), act as messen-
gers to maintain cellular functions through redox signal-
ing (9). However, when the production of ROS exceeds
the cellular antioxidant capacity and disturbs the balance
of the normal redox state, this can lead to oxidative
damage of proteins, lipids, and DNA. Increased oxida-
tive damage by ROS has been suggested to be a patho-
genetic mechanism of SSc (8,10–14). The imbalance of
the redox state can cause endothelial dysfunction and
injury (15), fibroblast proliferation (16), increased
type I collagen synthesis (11), and skewing of auto-
antibody production toward a Th2 profile (17); all of
these features are major characteristics of SSc. Free
radical generators, such as bleomycin, can result in a skin
fibrosis similar to that in SSc (18), and, in fact, induction
of fibrosis through the injection of bleomycin into mouse
skin serves as an animal model of SSc (19). Recently, an
animal model of SSc was established by injecting differ-
ent forms of ROS subcutaneously (20). N-acetylcysteine
(NAC), a thiol antioxidant, decreases the production
of O2
 in vitro (11), and shows promising results in
alleviating the symptoms of SSc (14,21–23). NAC is also
used as a treatment for idiopathic pulmonary fibrosis
(24). These studies imply that there may be a thiol-
oxidation mechanism involved in the development of
oxidative stress in SSc, since NAC not only acts as a free
radical scavenger (25), but also acts specifically on
protein thiols to support glutathione synthesis and gen-
erate free sulfhydryl groups (27).
The protein tyrosine phosphatase (PTP) family
comprises a group of PTPs that act as critical regulators
of a variety of cellular signaling pathways, including the
PDGFR pathway. These PTPs act by dephosphorylating
the activation signals elicited by protein tyrosine kinases.
PTPs are characterized by their signature motif,
HC(X)5R, which contains a cysteine (Cys) residue that is
essential for their catalytic activity. The low pKa of this
Cys residue allows it to function as a nucleophile, but
also makes it susceptible to oxidation. Several studies
have shown that the Cys residue in various PTPs is
oxidized in the presence of ROS (28,29). These obser-
vations imply that the increased levels of ROS in sclero-
derma skin lesions can oxidize PTPs that are involved in
the PDGFR signaling pathway.
In this study, we examined the effect of excessive
oxidative stress on PTP1B, a phosphatase that has been
shown to dephosphorylate the PDGFR (30,31). The
effect of the thiol antioxidant NAC on cellular ROS
production, PDGFR phosphorylation, tyrosine-
phosphorylated proteins, and PTP1B activity was also
investigated.
MATERIALS AND METHODS
Cell culture. Both normal and SSc dermal fibroblasts
(32) were kindly provided by Dr. Sergio Jimenez (Thomas
Jefferson University, Philadelphia, PA). SSc cells were ob-
tained from the forearm of patients with diffuse SSc (ages
32–57 years). All fibroblasts were maintained in RPMI me-
dium containing 10% fetal bovine serum (FBS) with penicillin
and streptomycin. The cells were switched to RPMI medium
containing 0.1% FBS and incubated for 24 hours, before being
stimulated with PDGF-BB (30 ng/ml; R&D Systems). Cells at
passages 6–12 were used.
Superoxide detection. Two days before immunostain-
ing analyses were performed, normal and SSc dermal fibro-
blasts were switched to RPMI medium containing 0.1% FBS,
to avoid the effect of FBS on O2
 production. In some
experiments, 20 mM NAC (Sigma-Aldrich) was added to the
cell culture medium. Cellular O2
 was measured in the cells
using dihydroethidium, while the nuclei were stained with
DAPI (both from Invitrogen). Fluorescence was detected
using an Olympus FV-500 confocal microscope, and photo-
graphs were taken at a magnification of 400.
Extraction of messenger RNA (mRNA) and quantita-
tive reverse transcription–polymerase chain reaction (qRT-
PCR). Total RNA was isolated using RNeasy Mini isolation
kits (Qiagen). Complementary DNA (cDNA) was prepared
using Verso cDNA synthesis kits (Thermo Scientific). Quanti-
tative PCR was performed using Platinum qPCR SYBR Green
Supermix-UDG (Invitrogen), with specific primers for human
PTP1B, COL1, and -actin. All samples were run in duplicate
using a Mastercycler ep realplex thermal cycler (Eppendorf),
with results analyzed using Eppendorf software.
Detection of PDGFR phosphorylation. Both normal
and SSc dermal fibroblasts were incubated with or without 20
mM NAC overnight, and then stimulated with PDGF. Cell
lysates were obtained, and an equal amount of lysate proteins
was incubated overnight at 4°C with immobilized mouse
anti-human monoclonal antibodies to phosphorylated tyrosine
(Cell Signaling Technology). Rabbit anti-human antibodies to
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PDGFR (Cell Signaling Technology) were used to probe for
phosphorylated PDGFR after the cells had been subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting. The immunoprecipitated
tyrosine-phosphorylated proteins were detected using the
mouse anti-human phosphorylated tyrosine antibody.
Immunofluorescence. For immunofluorescence analy-
ses, the cells were grown in 8-well chambers and then fixed and
blocked, before being probed with mouse anti-human type I
collagen monoclonal antibodies (Abcam). The cells were sub-
sequently incubated with Alexa Fluor–conjugated donkey anti-
mouse antibodies (Invitrogen). The nuclei were stained using
DAPI.
Western blotting and immunoprecipitation. Equal
amounts of cell lysate were loaded onto polyacrylamide gels
and separated by SDS-PAGE. The proteins were then trans-
ferred onto nitrocellulose membranes via Western blotting.
The blots were probed with either PTP1B (Abcam), phosphor-
ylated or total ERK-1/2 (both from Cell Signaling Technolo-
gies), oxidized PTPs (R&D Systems), or -actin (Sigma-
Aldrich). The blots were scanned and densitometric analysis
was carried out using Un-Scan-It software (Silk Scientific).
Immunoprecipitation was performed by incubating equal
amounts of protein from normal and SSc dermal fibroblasts
with a human anti-rabbit PTP1B antibody (20 g/mg protein;
Novus Biologicals). Rabbit IgG (Thermo Scientific) was incor-
porated as a negative control. The proteins captured by the
Protein A/G beads were eluted and subjected to SDS-PAGE
and Western blotting. The blot was then probed with a mouse
anti-human oxidized PTP antibody and rabbit anti-human
PTP1B antibody.
PTP1B activity assay. The PTP1B activity assay was
carried out using a PTP1B DuoSet IC kit (R&D Systems).
Mouse anti-human PTP1B antibodies that capture both active
and inactive PTP1B were immobilized. After washing away
unbound proteins, a synthetic phosphopeptide substrate that
was dephosphorylated by active phosphatases to generate free
phosphate and unphosphorylated peptide was added. The free
phosphate was detected by a sensitive dye-binding assay, using
malachite green and molybdic acid. By calculating the rate of
phosphate release, the activity of the phosphatase was deter-
mined.
PTP1B-knockdown studies. Normal dermal fibroblasts
were plated in 6-well plates and allowed to grow to 60%
confluence. The cells were then transfected with either 50 nM
control small interfering RNA (siRNA) (Invitrogen) or 50 nM
PTP1B siRNA (Santa Cruz Biotechnology) for 72 hours in
RPMI medium containing 10% FBS. Both PTP1B and COL1
levels were then quantified by qPCR.
Analysis of free thiol content. Free sulfhydryl groups
on proteins were determined using 5,5-dithiobis(2-
nitrobenzoic acid) (DTNB). Briefly, the cell lysates were mixed
with Tris-EDTA buffer (0.25M Tris base and 20 mM EDTA;
pH 8.2). The absorbance of the mixture was measured at 412
nm. DTNB in methanol was then added, followed by incuba-
tion for 15 minutes, and the absorbance was again measured at
412 nm. After subtracting the absorbance obtained before
adding DTNB, the net absorbance was used to calculate the
thiol content in the samples using a molar extinction coeffi-
cient of 13,600M/cm at 412 nm, which was normalized to the
level of total cellular protein, with results expressed as M/mg
protein.
Statistical analysis. Results are expressed as the
mean  SEM. The significance of differences between groups
was determined by Student’s t-test. P values less than 0.05, in
2-tailed analyses, were considered significant.
RESULTS
Superoxide production in dermal fibroblasts. As
shown in Figure 1, our results indicated that O2

production was significantly higher in SSc dermal fibro-
blasts compared to normal cells. In the presence of
NAC, a thiol antioxidant, the level of O2
 was signifi-
cantly reduced in SSc dermal fibroblasts.
Thiol content in normal and SSc dermal fibro-
blasts. In normal dermal fibroblasts, the mean  SEM
total free thiol content was 464  18 M/mg protein,
while in SSc dermal fibroblasts, it was significantly lower
(344  15 M/mg protein) (P  0.01; n  3 per group).
These results suggest that a portion of the protein thiols
in SSc dermal fibroblasts was modified into oxidation
products that do not react with DTNB. These findings
also confirm the observed pattern of O2
 staining in the
cells (Figure 1) and suggest that there is increased
oxidative stress in SSc dermal fibroblasts compared to
normal cells.
Phosphorylation of PDGFR after PDGF stimu-
lation. In normal dermal fibroblasts, PDGF-stimulated
phosphorylation of PDGFR reached maximum levels
after 10 minutes of stimulation (P  0.05 versus un-
stimulated cells) and returned to basal levels at 1 hour,
as shown in Figure 2A. In contrast, in SSc dermal
fibroblasts, PDGFR was maximally phosphorylated after
10 minutes of PDGF stimulation but remained phos-
phorylated after 1 hour of stimulation (P  0.05 versus
unstimulated cells at both time points). Within 30 min-
utes of stimulation, the extent of phosphorylation of
PDGFR in SSc dermal fibroblasts was significantly
higher than that in normal cells (P 0.05). These results
suggest that phosphatases that dephosphorylate the
PDGFR, such as PTP1B, might be deficient or inacti-
vated in SSc dermal fibroblasts.
To determine whether oxidative stress plays a
role in the prolonged PDGFR phosphorylation seen in
SSc dermal fibroblasts, NAC was added to the cell
culture medium and tyrosine-phosphorylated proteins
were immunoprecipitated. As shown in Figure 2B, in the
presence of NAC, phosphorylation of the PDGFR oc-
curred after 10 minutes of PDGF stimulation and con-
tinued up to 30 minutes in normal dermal fibroblasts. A
similar pattern was observed in SSc dermal fibroblasts,
although lower levels of phosphorylation were observed
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Figure 1. Production of superoxide (O2
 ) in normal (NL) and sys-
temic sclerosis (SSc) dermal fibroblasts, as detected by fluorescence
microscopy. Normal dermal fibroblasts and SSc dermal fibroblasts
were treated with dihydroethidium, an O2
 trap that releases red
fluorescence when it encounters O2
 . Nuclei were counterstained with
DAPI. Staining was detected using a fluorescence microscope and
images were obtained at an original magnification of 400. Before
treatment with N-acetylcysteine (NAC), a significant amount of O2

was detected in SSc fibroblasts compared to normal fibroblasts. In the
presence of NAC, O2
 production was decreased in SSc fibroblasts,
whereas treatment with NAC had no effect on normal fibroblasts.
Representative images of cells from 1 of 3 normal subjects and 1 of 3
SSc patients are shown.
Figure 2. Platelet-derived growth factor (PDGF) stimulation of phos-
phorylation of the PDGF receptor (PDGFR) and other proteins in
normal (NL) and systemic sclerosis (SSc) dermal fibroblasts. A and B,
Stimulation of PDGFR phosphorylation in the absence or presence of
N-acetylcysteine (NAC). In the absence of NAC (A), PDGF signifi-
cantly stimulated PDGFR phosphorylation, when compared to basal
(not-stimulated [NS]) levels, in normal cells after 10 minutes and 30
minutes, while in SSc fibroblasts, PDGFR phosphorylation increased
significantly from basal levels up to 1 hour. At 30 minutes, the level of
PDGFR phosphorylation in SSc dermal fibroblasts was significantly
higher than that in normal cells. In the presence of NAC (B), PDGFR
phosphorylation was observed after 10 minutes and 30 minutes of
stimulation in both normal and SSc dermal fibroblasts. PDGF stimu-
lated significant levels of PDGFR phosphorylation, when compared
to basal levels, in SSc dermal fibroblasts at 10 and 30 minutes. The
intensity of PDGFR phosphorylation was significantly lower in the
presence of NAC in both normal and SSc dermal fibroblasts. Results
in A and B are the mean SEM arbitrary units of optical density (OD)
in 3 samples per group, with detection by Western blotting using
-actin as a positive control. C and D, Phosphorylation of multiple
proteins in the absence or presence of NAC, as detected by Western
blotting. In the absence of NAC (C), multiple proteins were phosphor-
ylated in both normal and SSc dermal fibroblasts after stimulation with
PDGF for up to 1 hour, and more tyrosine-phosphorylated proteins
were induced in SSc cells compared to normal cells. In the presence of
NAC (D), PDGF stimulated protein tyrosine phosphorylation in both
normal and SSc dermal fibroblasts, but with less intensity compared to
that in the absence of NAC.
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in SSc fibroblasts compared to normal cells after 30
minutes of stimulation.
We found that the addition of NAC significantly
decreased the intensity of PDGFR phosphorylation in
both normal and SSc dermal fibroblasts. When we
compared the time course of PDGFR phosphorylation
in the presence and absence of NAC (Figures 2A and B),
we found that activation of the PDGFR occurred
through dimerization after PDGF stimulation of the
cells for a period of 10 minutes up to 30 minutes.
Protein tyrosine phosphorylation after PDGF
stimulation. To examine the effect of NAC on other
tyrosine-phosphorylated proteins, the immunoprecipi-
tated proteins (as shown in Figures 2A and B) were
subjected to Western blotting and probed with mouse
anti-human protein tyrosine phosphorylation antibod-
ies. In these blots, the 25-kd and 50-kd bands represent
the light and heavy chains of IgG, respectively.
The expression patterns of the tyrosine-
phosphorylated proteins in the absence of NAC (Figure
2C) showed that PDGF induced phosphorylation of
multiple proteins in both normal and SSc dermal fibro-
blasts. Most of these phosphorylated proteins were still
visible at 1 hour after stimulation with PDGF. More-
over, more proteins were phosphorylated in SSc dermal
fibroblasts compared to normal cells. In the presence of
NAC (Figure 2D), fewer proteins were phosphorylated
by PDGF in both normal and SSc dermal fibroblasts,
consistent with the results observed for phosphorylation
of the PDGFR.
These results suggest that in addition to the
PDGFR pathway, many more proteins are phosphory-
lated in SSc dermal fibroblasts, and NAC affects not
only the PDGFR, but also many other proteins. Since
NAC decreases the production of cellular ROS, these
findings indicate that the prolonged phosphorylation of
PDGFR in SSc dermal fibroblasts might be attributed to
oxidative inactivation of multiple thiol-sensitive phos-
phatases that dephosphorylate the PDGFR. Since PTPs
tend to have multiple substrates, we hypothesized that
the increased number of phosphorylated proteins ob-
served might be attributed to the inactivation of a
certain PTP.
Phosphorylation of ERK-1/2 after PDGF stimu-
lation. When normal dermal fibroblasts were stimulated
with PDGF, ERK-1/2 phosphorylation reached maxi-
mum levels at 45 minutes of stimulation, and returned to
baseline levels at 4 hours (Figure 3A). In contrast, in SSc
dermal fibroblasts, significant phosphorylation of ERK-
1/2 was observed after 10 minutes of PDGF stimulation,
and persisted up to 4 hours.
The extent of ERK-1/2 phosphorylation was sig-
nificantly different between normal and SSc dermal
fibroblasts (P  0.05) after 4 hours of stimulation of the
cells with PDGF. These results are consistent with the
observed patterns of PDGFR phosphorylation (Figure
2A), in that the enhanced and prolonged phosphoryla-
tion of PDGFR led to enhanced and prolonged activa-
tion of its downstream signaling pathway, ERK-1/2, in
SSc dermal fibroblasts, while in normal cells, the profile
of PDGFR phosphorylation paralleled that of ERK-1/2
phosphorylation, with both showing a shorter time
course and less pronounced phosphorylation compared
with that in SSc cells.
Although the basal level of phosphorylated ERK-
1/2 was increased in both normal and SSc dermal
fibroblasts (P  0.05) (Figure 3A), incubation of the
cells in the presence of NAC did not result in further
significant ERK-1/2 phosphorylation in either normal or
SSc fibroblasts (P  0.05) (Figure 3B). The slight
increase in the basal level of phosphorylated ERK-1/2 in
the presence of NAC might be due to the effects of NAC
on negative regulators of the MAPK pathway. These
results also suggest that the beneficial effect of NAC on
type I collagen production might be due, in part, to some
other factors, such as an effect on the expression of
matrix metalloproteinases. Taken together, these results
show that the PDGFR and its downstream signaling
pathway were activated to a greater extent in SSc dermal
fibroblasts, and NAC, a thiol antioxidant, could alter the
extent of PDGF stimulation in both normal and SSc
dermal fibroblasts.
Expression of type I collagen in normal and
SSc dermal fibroblasts. At baseline and after 10 minutes
of PDGF stimulation, COL1 mRNA levels were signif-
icantly higher in SSc dermal fibroblasts compared to
normal dermal fibroblasts (P  0.05) (Figure 3C). After
4 hours of PDGF stimulation, COL1 mRNA levels were
significantly decreased in SSc dermal fibroblasts when
compared to the levels in unstimulated SSc cells. Treat-
ment with NAC significantly decreased the COL1
mRNA levels in SSc dermal fibroblasts at several time
points after incubation of the cells with PDGF, whereas
NAC had no significant effect on normal cells. At the
protein level, there was more staining for type I collagen
in SSc dermal fibroblasts compared to normal cells
(Figure 3D). In the presence of NAC, the expression of
type I collagen in SSc dermal fibroblasts decreased to
levels similar to those observed in normal cells.
These results characterize the final phase of the
response following PDGFR activation in SSc dermal
fibroblasts. In summary, enhanced PDGFR activation in
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SSc dermal fibroblasts leads to increased ERK-1/2 phos-
phorylation, which thereby induces more synthesis of
type I collagen. Treatment with NAC, which acts by
scavenging ROS and deactivating the PDGFR pathway,
results in a decrease in the synthesis of type I collagen in
SSc dermal fibroblasts.
Expression of PTP1B in normal and SSc dermal
fibroblasts. In the presence of PDGF, the levels of
PTP1B mRNA in normal dermal fibroblasts were
slightly increased after 2 hours and 4 hours of stimu-
lation, while the expression of PTP1B mRNA in SSc
dermal fibroblasts remained the same, as shown in
Figure 4A. When normal dermal fibroblasts were stim-
ulated with PDGF, the expression of PTP1B protein
increased gradually and was maximal after 45 minutes
of stimulation, and remained elevated after 2 hours of
stimulation (P  0.05 versus unstimulated cells at both
time points), whereas after 4 hours of stimulation, there
was no difference in PTP1B protein expression between
stimulated and unstimulated normal dermal fibroblasts
(Figure 4B). In contrast, similar to the results with
regard to mRNA expression (Figure 4A), when SSc
dermal fibroblasts were stimulated with PDGF for up to
4 hours, the expression of PTP1B protein remained the
same (Figure 4B).
In the basal state, there was no difference in
PTP1B protein expression between normal and SSc
dermal fibroblasts (mean  SEM optical density 0.46 
0.10 in unstimulated normal dermal fibroblasts versus
0.49  0.14 in unstimulated SSc dermal fibroblasts)
(Figure 4B). After 45 minutes of stimulation, the level of
PTP1B protein in SSc dermal fibroblasts was signifi-
cantly lower than that in normal cells (P  0.05).
Therefore, based on these results, it appears that in an
Figure 3. ERK-1/2 phosphorylation patterns and type I collagen production in normal (NL) and systemic sclerosis (SSc) dermal fibroblasts. A and
B, Platelet-derived growth factor (PDGF) stimulation of ERK-1/2 phosphorylation in the absence or presence of N-acetylcysteine (NAC). In the
absence of NAC (A), PDGF stimulated significant ERK-1/2 phosphorylation, when compared to basal (not-stimulated [NS]) levels, in normal cells
after 45 minutes and 2 hours. In SSc fibroblasts, ERK-1/2 phosphorylation increased significantly from 10 minutes up to 4 hours. The level of
ERK-1/2 phosphorylation in SSc dermal fibroblasts was significantly higher than that in normal cells after 4 hours of stimulation. In the presence
of NAC (B), although the basal level of ERK-1/2 phosphorylation was increased slightly in both normal and SSc cells, PDGF stimulation did not
result in further significant ERK-1/2 phosphorylation. Results in A and B are the mean  SEM arbitrary units of optical density (OD) in 3 samples
per group, with detection by Western blotting using -actin as a positive control. C and D, Expression of mRNA and protein for type I collagen.
In the absence of NAC, mRNA levels of the gene encoding type I collagen (C) were significantly higher in SSc fibroblasts compared to normal
fibroblasts. Treatment with NAC significantly decreased the mRNA levels in SSc cells, but had no significant effect on normal dermal fibroblasts.
Similarly, in the absence of NAC, a significant amount of type I collagen (Col I) protein (D) was detected in SSc fibroblasts compared to normal
fibroblasts, and treatment with NAC led to decreased protein expression in SSc fibroblasts. Bars in C show the mean  SEM mRNA expression,
relative to -actin, in 3 samples per group. In D, representative images of cells from 1 of 3 normal subjects and 1 of 3 SSc patients are shown (original
magnification  400); rabbit IgG was used as a negative control.
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unstimulated state, the same amount of PTP1B is pres-
ent in normal dermal fibroblasts and SSc dermal fibro-
blasts. However, when the cells are stimulated with
PDGF, the level of PTP1B increases in normal cells, but
not in SSc dermal fibroblasts.
Enzyme activity of PTP1B in normal and SSc
dermal fibroblasts. PTP1B activity was significantly
lower in SSc dermal fibroblasts compared to normal cells
(mean  SEM 11.9  1.3 nmoles versus 20.1  2.7
nmoles; P  0.05) (Figure 4C). In contrast, in the
presence of the antioxidant NAC, PTP1B activity was
restored in SSc dermal fibroblasts (mean  SEM 19.2 
2.1 nmoles), compared to a level of 16.2  0.4 nmoles in
normal dermal fibroblasts in the presence of NAC.
Therefore, these findings indicate that when excess O2

is present in SSc dermal fibroblasts, the activity of
PTP1B is inactivated, whereas when O2
 is eliminated
by NAC, the activity of PTP1B is restored. These results
imply that the increased oxidative stress in SSc dermal
fibroblasts inactivates PTP1B, resulting in increased
PDGFR phosphorylation, ERK-1/2 activation, and in-
creased type I collagen synthesis. The presence of NAC
not only eliminates O2
 in these cells, but also restores
PTP1B activity, thus decreasing the extent of PDGFR
phosphorylation and its downstream events.
PTP1B expression and type I collagen produc-
tion. To elucidate the direct involvement of PTP1B in
type I collagen production, we knocked down PTP1B
expression in normal dermal fibroblasts and assessed the
expression of COL1 mRNA. As shown in Figure 4D,
PTP1B mRNA expression was significantly knocked
down by siRNA treatment (P  0.05 versus control).
Under this condition, COL1 mRNA expression in nor-
mal dermal fibroblasts increased by 40% (P  0.05
versus control). These results suggest that PTP1B, pos-
sibly through the PDGFR pathway, controls type I
Figure 4. Expression and enzymatic activity of protein tyrosine phosphatase 1B (PTP1B) in normal (NL) and systemic sclerosis (SSc) dermal
fibroblasts. A and B, Platelet-derived growth factor (PDGF) stimulation of PTP1B mRNA and protein expression. The expression of PTP1B mRNA
(A) was not significantly different in normal and SSc dermal fibroblasts at basal (not-stimulated [NS]) levels or up to 4 hours after stimulation with
PDGF. At the protein level (B), PDGF-stimulated PTP1B production was significantly higher, when compared to basal levels, after 45 minutes and
2 hours of stimulation in normal cells. However, in SSc cells, incubation of the cells with PDGF did not alter the expression of PTP1B protein. At
45 minutes of stimulation with PDGF, there was a significant difference in PTP1B protein expression between normal and SSc cells (P  0.05).
Results in A are the mean SEM mRNA expression relative to -actin and results in B are the mean SEM arbitrary units of optical density (OD)
in 4 samples per group, along with Western blots using -actin as a positive control. C, PTP1B activity in the absence (basal media) or presence of
N-acetylcysteine (NAC). In medium without NAC, the PTP1B activity was significantly lower in SSc dermal fibroblasts compared to normal dermal
fibroblasts. In the presence of NAC, the PTP1B activity was restored in SSc cells. D, Effects of small interfering RNA (siRNA) knockdown of PTP1B
in normal dermal fibroblasts. When PTP1B mRNA expression was significantly knocked down by the siRNA (left), this was paralleled by a significant
increase in the expression of type I collagen (Col I) mRNA (right) in normal dermal fibroblasts, mimicking the findings in SSc dermal fibroblasts.
Bars in C and D show the mean  SEM of 4 samples per group. Con  control.
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collagen production in dermal fibroblasts. This further
supports the notion that PTP1B plays a significant role
in skin fibrosis.
Oxidation of PTPs in normal and SSc dermal
fibroblasts. To examine whether PTPs are oxidized in
dermal fibroblasts, oxidized PTPs were probed using
antibodies that recognize the oxidized Cys residue at
their active site. The oxidized PTP profiles in 3 normal
healthy subjects and 5 patients with SSc are shown in
Figure 5A. In the dermal fibroblasts from the 3 normal
subjects, 2 protein bands were observed, although in the
fibroblasts from subject 3, a stronger signal intensity was
observed and one of the bands was located at a higher
molecular weight than that in fibroblasts from the other
2 subjects. In SSc dermal fibroblasts, at least 3 PTPs
were oxidized, all of which had stronger signal intensities
compared to those in normal dermal cells.
The profile of PTP expression appeared slightly
different in each SSc patient, although oxidation was
consistent for the PTP at the 50-kd band. This latter
band could represent PTP1B. We then probed PTP1B in
the cell lysates with the same antibody as used in
Western blotting. The results showed that 2-fold more
oxidized PTP1B was present in SSc dermal fibroblasts
compared to normal dermal fibroblasts (P 0.05; n 3)
(Figure 5B). These results suggest that the inactivation
of PTP1B can be attributed to oxidation of its active site.
DISCUSSION
In this study, we provide evidence that PTP1B is
inactivated by ROS in SSc dermal fibroblasts, leading
to prolonged phosphorylation of the PDGFR. As sum-
marized in Figure 6, we have shown that the levels of
ROS are elevated in SSc dermal fibroblasts compared
to normal cells. The increased oxidative stress leads to
a significant decrease in the total protein thiol groups
in SSc dermal fibroblasts, as well as oxidation at the
Cys-active site of PTP1B. Oxidation of PTPs leads to
inactivation of their phosphatase activity, resulting in a
profile of prolonged phosphorylation of PDGFR and
ERK-1/2 as well as increased type I collagen expression
in SSc dermal fibroblasts. In addition, we have demon-
strated a direct relationship between PTP1B expression
and COL1 synthesis, using PTP1B-knockdown experi-
ments in normal dermal fibroblasts. Our findings with
regard to the inclusion of NAC, a thiol antioxidant, in
the cell cultures reconfirm the impact of oxidative stress
on PTP1B, as lower PTP1B activity was observed to be
present in conjunction with high levels of O2
 in SSc
Figure 5. Oxidation of protein tyrosine phosphatases (PTPs) in normal and systemic sclerosis (SSc) dermal fibroblasts. Oxidized PTPs in normal
and SSc dermal fibroblasts were visualized on Western blots using mouse anti–oxidized human PTP antibodies. Equal amounts of protein were
subjected to immunoprecipitation using rabbit anti-human PTP1B antibodies. The blot was then probed with mouse anti–oxidized human PTP
antibodies. A, Overall, more PTPs were oxidized in SSc dermal fibroblasts (n  5) compared to normal dermal fibroblasts (n  3). In normal cells,
2 bands were observed in all subjects, although at different molecular weights. In SSc dermal fibroblasts, at least 3 PTPs were oxidized. The 50-kd
protein, which is postulated to be PTP1B, was oxidized in all SSc dermal fibroblasts. -actin was used as a positive control. B, Results of
immunoprecipitation confirmed that the 50-kd protein was PTP1B. There was significantly more oxidized PTP1B in SSc dermal fibroblasts compared
to normal dermal fibroblasts. Bars show the mean  SEM of 3 samples per group.
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dermal fibroblasts, and when the O2
 was eliminated by
NAC, not only was the PTP1B activity restored, but also
the levels of PDGFR and its downstream events, includ-
ing type I collagen expression, were similar to those
found in normal cells. Our results suggest a new mech-
anism by which oxidative stress promotes a profibrotic
phenotype in SSc dermal fibroblasts through oxidative
inactivation of phosphatases, leading to pronounced
PDGFR activation.
Our findings of increased ROS production in SSc
dermal fibroblasts are consistent with those reported
previously (8,11,12,14,33). The source of O2
 is believed
to be NADPH oxidase. When SSc dermal fibroblasts
were treated with diphenylene iodonium, which acts as
an NADPH oxidase inhibitor, O2
 levels were dimin-
ished (11). In addition, increased expression of the
NADPH oxidase subunits was observed in monocytes
and dermal fibroblasts isolated from SSc patients
(11,12). Because protein thiols are very sensitive to ROS
and can be oxidized, we measured free thiols in the cells,
as another marker of oxidative stress. We showed that
the free thiol content in SSc dermal fibroblasts was
significantly lower than that in normal cells, again sug-
gesting the existence of oxidative stress in SSc. Signifi-
cantly reduced levels of total plasma thiols in SSc
patients compared with normal subjects have been dem-
onstrated previously (34,35).
In this study we hypothesized that the prolonged
phosphorylation of the PDGFR in SSc fibroblasts is a
result of decreased expression of, or ROS inactivation
of, PTPs. We cannot rule out the role of protein kinases
in driving PDGFR phosphorylation, as studies have
emphasized the importance of these enzymes in the
pathogenesis of SSc (36). However, it appears that
protein tyrosine kinases are not direct targets of ROS. In
addition, protein tyrosine phosphorylation is controlled
through the coordinated actions of tyrosine kinases and
PTPs. These proteins not only have housekeeping func-
tions, but also are highly regulated and play crucial roles
in many cell functions and in different diseases. A recent
study showed that the expression of protein phosphatase
2A was significantly lower in SSc fibroblasts (37). The
Figure 6. Summary of the mechanisms of protein tyrosine phosphatase 1B (PTP1B) inactivation by oxidative stress in systemic sclerosis (SSc)
dermal fibroblasts. In normal dermal fibroblasts, adequate amounts of reactive oxygen species (ROS) perform their role in redox signaling and are
not harmful in oxidizing cellular proteins. When platelet-derived growth factor (PDGF) binds to its receptor, PDGFR, the receptor is
phosphorylated and downstream signaling pathways, such as ERK-1/2, are activated, leading to a response, exemplified by type I collagen
production. PTP1B is active and controls the extent of phosphorylation on the PDGFR. In SSc dermal fibroblasts, the increased production of ROS
inactivates PTP1B through oxidation of the cysteine residue in its active site. When PDGF binds to its receptor, the prolonged phosphorylation of
the PDGFR due to the inactivation of PTP1B results in an increased downstream response. In SSc fibroblasts in the presence of the thiol antioxidant
N-acetylcysteine (NAC), levels of ROS decrease, the oxidized cysteine residue on PTP1B is reduced, the PTP1B activity is restored, and the response
pattern returns to that observed at baseline. The red solid arrow indicates oxidation, the broken arrow indicates reduced oxidation, the solid crossbar
indicates dephosphorylation, and the broken crossbar indicates inability to dephosphorylate. P  tyrosine phosphorylation; SH  free thiols;
SOxH  oxidized thiols.
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authors suggested that this led to constitutive activation
of the TGF pathway and enhanced ERK-1/2 phosphor-
ylation, which was also seen in the present study.
We examined the expression and function of
PTP1B, which has been reported to be a negative
regulator of receptor tyrosine kinases such as PDGFR
(30,31). The association between PTP1B and PDGFR is
further supported by a study using PTP1B-knockout
mice (38). In addition to the PDGFR pathway, PTP1B
appears to be a negative regulator in both insulin and
leptin signaling pathways (39,40). Epidermal growth
factor receptor (41) and tyrosine-phosphorylated pro-
teins such as STAT-5 (42) have also been shown to be
targets of PTP1B. Although the expression of PTP1B
was similar in normal dermal fibroblasts and SSc dermal
fibroblasts (Figure 4B), the activity of PTP1B was sig-
nificantly lower in SSc fibroblasts, suggesting that only a
portion of the expressed PTP1B is active in SSc fibro-
blasts.
We further showed that the inactivation of
PTP1B is due to oxidation of its active site. Oxidation of
PTPs is not rare. In fact, reversible and transient oxida-
tion of PTPs is regarded as a redox regulatory mecha-
nism for receptor tyrosine kinases to control their phos-
phorylation state (43). However, when a constant and
large amount of ROS is present, prolonged inactivation
of PTP activity may occur. Indeed, it has been shown
that in human cancer cells, increased production of ROS
can lead to production of sulfenic, sulfinic, and sulfonic
acids at the active site of PTP1B, resulting in its inacti-
vation (44). Similar to these findings, we showed that
increased levels of ROS in SSc dermal fibroblasts not
only inactivated PTP1B, but also oxidized at least 3
PTPs. The decreased antioxidant capacity in SSc (45)
may also exacerbate these mechanisms of inactivation.
The reason for the increased expression of
PTP1B in normal cells after PDGF stimulation requires
further investigation. Since protein synthesis requires a
prolonged time course, we postulate that the increase in
PTP1B might be due to release of PTP1B from the
pool of phosphorylated or sumoylated proteins, since
the antibody that was used recognizes only free PTP1B.
This might be a defense mechanism in normal cells to
counteract the activation of the PDGFR. However, this
mechanism appears to be lost in SSc dermal fibroblasts,
as we found that the expression of PTP1B did not
change after PDGF stimulation of SSc cells.
Since oxidative stress in SSc dermal fibroblasts
was accompanied by a significant reduction in free thiol
content, we hypothesize that NAC, a thiol antioxidant
(25–27) that has shown beneficial effects in SSc
(11,14,20–23), will benefit the cells by decreasing cellular
ROS levels and replenishing free cellular thiols. Indeed,
we showed that treatment of the cells with NAC not only
decreased the cellular levels of O2
 , but also restored
PTP1B activity, which led to improvement in PDGFR
phosphorylation and in the type I collagen expression
profile. Our results are consistent with those in a previ-
ous study in which NAC prevented serum-induced
PDGFR phosphorylation and its downstream signaling
pathways by scavenging O2
 produced by NADPH
oxidase (46). Another study showed that in cultured
vascular smooth muscle cells, NAC reduced PDGFR
phosphorylation and increased PTP activity (47).
PTP1B is not the only phosphatase that regulates
the phosphorylation state of PDGFR. A number of
thiol-sensitive phosphatases, such as SH2 domain–
containing phosphatase 2 (SHP-2) (30) and density-
enhanced phosphatase 1 (DEP-1) (48), have been shown
to dephosphorylate the PDGFR. Preliminary results
show that the expression of SHP-2 seems to differ in SSc
fibroblasts compared to normal cells, when the cells are
treated with PDGF. In addition, in cultures of unstimu-
lated cells, the expression of DEP-1 appears to be higher
in SSc fibroblasts compared with normal fibroblasts
(results not shown). Whether the phosphatase activities
of DEP-1 and SHP-2 are affected by ROS needs further
investigation. If indeed DEP-1 and SHP-2 are inacti-
vated, the antioxidative effect of NAC on PDGFR
phosphorylation and protein tyrosine phosphorylation
may therefore be attributed to restoration of the activi-
ties of a combination of phosphatases. Nonetheless, we
showed that at least one phosphatase, PTP1B, is inactive
when excessive O2
 is present in SSc dermal fibroblasts,
and its activity is restored when NAC is present, with a
simultaneous change in the PDGFR phosphorylation
pattern.
In conclusion, our findings provide evidence that
the increased oxidative stress in SSc dermal fibroblasts
oxidizes PTP1B and renders it inactive, and thereby
amplifies the PDGFR signaling pathway. We not only
introduce a new mechanism for the role of oxidative
stress in the pathogenesis of fibrosis in SSc, but also
provide a novel molecular pathway by which NAC
therapy may act on ROS and PTP1B to benefit SSc
patients.
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